HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

APOE E4 is associated with impaired self-declared cognition but not disease risk or age of onset in Nigerians with Parkinson's disease.

Abstract
The relationship between APOE polymorphisms and Parkinson's disease (PD) in black Africans has not been previously investigated. We evaluated the association between APOE polymorphic variability and self-declared cognition in 1100 Nigerians with PD and 1097 age-matched healthy controls. Cognition in PD was assessed using the single item cognition question (item 1.1) of the MDS-UPDRS. APOE genotype and allele frequencies did not differ between PD and controls (p > 0.05). No allelic or genotypic association was observed between APOE and age at onset of PD. In PD, APOE ε4/ε4 conferred a two-fold risk of cognitive impairment compared to one or no ε4 (HR: 2.09 (95% CI: 1.13-3.89; p = 0.02)), while APOE ε2 was associated with modest protection against cognitive impairment (HR: 0.41 (95% CI 0.19-0.99, p = 0.02)). Of 773 PD with motor phenotype and APOE characterized, tremor-dominant (TD) phenotype predominated significantly in ε2 carriers (87/135, 64.4%) compared to 22.2% in persons with postural instability/gait difficulty (PIGD) (30/135) and 13.3% in indeterminate (ID) (18/135, 13.3%) (p = 0.037). Although the frequency of the TD phenotype was highest in homozygous ε2 carriers (85.7%), the distribution of motor phenotypes across the six genotypes did not differ significantly (p = 0.18). Altogether, our findings support previous studies in other ethnicities, implying a role for APOE ε4 and ε2 as risk and protective factors, respectively, for cognitive impairment in PD.
AuthorsNjideka U Okubadejo, Olaitan Okunoye, Oluwadamilola O Ojo, Babawale Arabambi, Rufus O Akinyemi, Godwin O Osaigbovo, Sani A Abubakar, Emmanuel U Iwuozo, Kolawole W Wahab, Osigwe P Agabi, Uchechi Agulanna, Frank A Imarhiagbe, Oladunni V Abiodun, Charles O Achoru, Akintunde A Adebowale, Olaleye Adeniji, John E Akpekpe, Mohammed W Ali, Ifeyinwa Ani-Osheku, Ohwotemu Arigbodi, Salisu A Balarabe, Abiodun H Bello, Oluchi S Ekenze, Cyril O Erameh, Temitope H Farombi, Michael B Fawale, Morenikeji A Komolafe, Paul O Nwani, Ernest O Nwazor, Yakub Nyandaiti, Emmanuel E Obehighe, Yahaya O Obiabo, Olanike A Odeniyi, Francis E Odiase, Francis I Ojini, Gerald A Onwuegbuzie, Nosakhare Osemwegie, Olajumoke O Oshinaike, Folajimi M Otubogun, Shyngle I Oyakhire, Funlola T Taiwo, Uduak E Williams, Simon Ozomma, Yusuf Zubair, Dena Hernandez, Sara Bandres-Ciga, Cornelis Blauwendraat, Andrew Singleton, Henry Houlden, John Hardy, Mie Rizig
JournalNPJ Parkinson's disease (NPJ Parkinsons Dis) Vol. 8 Issue 1 Pg. 155 (Nov 12 2022) ISSN: 2373-8057 [Print] United States
PMID36371506 (Publication Type: Journal Article)
Copyright© 2022. The Author(s).

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: